PAVM

Company Overview — What Does PAVmed Inc. Do?

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York. PAVmed Inc. (PAVM) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Lishan Aklog and employs approximately 90 people, headquartered in New York, New York. With a market capitalization of $15M, PAVM is one of the notable companies in the Healthcare sector.

PAVmed Inc. (PAVM) Stock Rating — Reduce (April 2026)

As of April 2026, PAVmed Inc. receives a Reduce rating with a composite score of 32.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PAVM ranks #2,302 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PAVmed Inc. ranks #272 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PAVM Stock Price and 52-Week Range

PAVmed Inc. (PAVM) currently trades at $9.74. The 52-week high for PAVM is $28.44, which means the stock is currently trading -65.7% from its annual peak. The 52-week low is $0.21, putting the stock 4540.5% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is PAVM Overvalued or Undervalued? — Valuation Analysis

PAVmed Inc. (PAVM) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.98x, compared to the Healthcare sector average of 23.63x — a discount of 96%. The price-to-book ratio stands at 2.69x, versus the sector average of 2.75x. The price-to-sales ratio is 58.94x, compared to 1.66x for the average Healthcare stock.

At current multiples, PAVmed Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PAVmed Inc. Profitability — ROE, Margins, and Quality Score

PAVmed Inc. (PAVM) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 273.5%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 157.2% versus the sector average of -33.1%.

On a margin basis, PAVmed Inc. reports gross margins of -492.9%, compared to 71.5% for the sector. The operating margin is -61174.0% (sector: -66.1%). Net profit margin stands at -21690.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -99.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PAVM Debt, Balance Sheet, and Financial Health

PAVmed Inc. has a debt-to-equity ratio of 74.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 0.17x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $7M. Cash and equivalents stand at $3M.

PAVM has a beta of 2.63, meaning it is more volatile than the broader market — a $10,000 investment in PAVM would be expected to move 162.7% more than the S&P 500 on any given day. The stability factor score for PAVmed Inc. is 8/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PAVmed Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PAVmed Inc. reported revenue of $1M and earnings per share (EPS) of $-5.63. Net income for the quarter was $61M. Gross margin was -492.9%. Operating income came in at $-27M.

In FY 2025, PAVmed Inc. reported revenue of $71,000 and earnings per share (EPS) of $-5.63. Net income for the quarter was $-2M. Gross margin was -207.0%. Revenue grew -97.6% year-over-year compared to FY 2024. Operating income came in at $-22M.

In Q3 2025, PAVmed Inc. reported revenue of $5,000 and earnings per share (EPS) of $-0.29. Net income for the quarter was $-6M. Gross margin was -1000.0%. Revenue grew -99.5% year-over-year compared to Q3 2024. Operating income came in at $-5M.

In Q2 2025, PAVmed Inc. reported revenue of $6,000 and earnings per share (EPS) of $-0.74. Net income for the quarter was $-12M. Gross margin was -583.3%. Revenue grew -99.4% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, PAVmed Inc. has demonstrated a growth trajectory, with revenue expanding from $1M to $1M. Investors analyzing PAVM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PAVM Dividend Yield and Income Analysis

PAVmed Inc. (PAVM) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PAVM Momentum and Technical Analysis Profile

PAVmed Inc. (PAVM) has a momentum factor score of 79/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 34/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PAVM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PAVmed Inc. (PAVM) ranks #272 out of 838 stocks based on the Blank Capital composite score. This places PAVM in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PAVM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PAVM vs S&P 500 (SPY) comparison to assess how PAVmed Inc. stacks up against the broader market across all factor dimensions.

PAVM Next Earnings Date

No upcoming earnings date has been announced for PAVmed Inc. (PAVM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PAVM? — Investment Thesis Summary

The quantitative profile for PAVmed Inc. suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Price momentum is positive at 79/100, suggesting the trend favors buyers. High volatility (stability score 8/100) increases portfolio risk.

In summary, PAVmed Inc. (PAVM) earns a Reduce rating with a composite score of 32.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PAVM stock.

Related Resources for PAVM Investors

Explore more research and tools: PAVM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PAVM head-to-head with peers: PAVM vs AZN, PAVM vs SLGL, PAVM vs VMD.